glp-1 truth serum podcast Understanding GLP-1 Weight Loss Medication

& Weissman, D

While rarely severe enough to cause discontinuation, it is a hallmark of the triple agonist mechanism, likely linked to glucagons influence on sensory pathways or metabolic shifts in the peripheral nervous system

But competition is coming from amylin agonists, which bring unique advantages that could position them to overtake GLP-1 as the preferred monotherapy or combination backbone without simply pushing for a bigger weight loss number

Both peptides were developed with the primary intent of exploring and leveraging their melanogenic (tanning) capabilities

I think this will exist and expand beyond the shortage dynamics